Dianthus Therapeutics
DNTH
140 hedge funds and large institutions have $1.84B invested in Dianthus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 13 closing their positions.
292% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 13
153% more capital invested
Capital invested by funds: $729M → $1.84B (+$1.11B)
83% more funds holding in top 10
Funds holding in top 10: 6 → 11 (+5)
37% more funds holding
Funds holding: 102 → 140 (+38)
26% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 34
23.88% more ownership
Funds ownership: 121.6% → 145.48% (+24%)
9% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $14.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$64M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.5M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$21.3M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$51.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$41.6M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$29.8M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$15.8M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$9.14M |
DNTH Hedge Fund Activity: Q3 2025 in Review
140 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2025, worth a combined $1.84B — up 153% from $729M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new DNTH positions and 13 closed out — a net gain of 38 holders — while 43 added to existing stakes and 34 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $64M. The largest seller was Vestal Point Capital, cutting an estimated $51.6M.
- 140 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2025, up from 102 in Q2 2025.
- Funds reported $1.84B of Dianthus Therapeutics stock for Q3 2025, up 153% quarter-over-quarter.
- 51 funds opened new Dianthus Therapeutics positions in Q3 2025 and 13 closed out, a net change of +38 holders.
- The largest Dianthus Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $64M added.
- The largest Dianthus Therapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $51.6M sold.
Based on aggregated 13F filings for Q3 2025.